In the last decade a number of particulate carrier systems have been developed to change the therapeutic efficacy of drugs after intravenous injection. Among these are nanopartitles, liposomes, gelatin and albumin microspheres. The objectives for designing these systems varied widely: from a sustained action to site specific delivery of the encapsulated drug. Critical points for the selection of a carrier system are: I) the ability of the carrier-homing device combination to deliver the drug at the desired sites; 2) the acute and chronic toxicity of these systems and their immunogenicity; 3) the preparation and shelf life of the products. For homing devices antibodies and certain glycolipids are under investigation. The results indicate that site specific delivery is hampered by the limited ability of the carriers to pass the wall of the blood vessels and the strong affinity of the cells of the reticulo-endothelial system (RES) for these "foreign" bodies. Therefore, target sites should be located either in the compartment of injection (general circulation) or in the cells of the RES. Distribution kinetics in vivo are susceptible to composition, size and charge of the Carrier system. A proper definition of the product is therefore essential to obtain results that are sufficiently reproducible. In this presentation some of the conclusions mentioned above will be illustrated and discussed in more detail. An increased drug selectivitv can in principle be obtained by covalently linking of drugs to a blodegradable carrier. The particular macromolecule should be specifically recognized by receptors for endocytosis on the cell surface of the organ or tissue where the drug is required for its action. A local drug delivery of potentially very toxic compounds may not only decrease undesirable side effects and toxicLty on other tissues ("passive targeting"), but can also produce a marked increase in potency of the drug ("active targeting").
In the last decade a number of particulate carrier systems have been developed to change the therapeutic efficacy of drugs after intravenous injection. Among these are nanopartitles, liposomes, gelatin and albumin microspheres. The objectives for designing these systems varied widely: from a sustained action to site specific delivery of the encapsulated drug. Critical points for the selection of a carrier system are: I) the ability of the carrier-homing device combination to deliver the drug at the desired sites; 2) the acute and chronic toxicity of these systems and their immunogenicity; 3) the preparation and shelf life of the products. For homing devices antibodies and certain glycolipids are under investigation. The results indicate that site specific delivery is hampered by the limited ability of the carriers to pass the wall of the blood vessels and the strong affinity of the cells of the reticulo-endothelial system (RES) for these "foreign" bodies. Therefore, target sites should be located either in the compartment of injection (general circulation) or in the cells of the RES. Distribution kinetics in vivo are susceptible to composition, size and charge of the Carrier system. A proper definition of the product is therefore essential to obtain results that are sufficiently reproducible. In this presentation some of the conclusions mentioned above will be illustrated and discussed in more detail. An increased drug selectivitv can in principle be obtained by covalently linking of drugs to a blodegradable carrier. The particular macromolecule should be specifically recognized by receptors for endocytosis on the cell surface of the organ or tissue where the drug is required for its action. A local drug delivery of potentially very toxic compounds may not only decrease undesirable side effects and toxicLty on other tissues ("passive targeting"), but can also produce a marked increase in potency of the drug ("active targeting").
The simplicity of the drug targeting concept however is inversely related to the complexity in the proper design of therapeutic dosage forms for human use. Apart from pharmaceutical problems such as chemical stab [-lity, practical routes of administration and costs of manufacturing, chronic toxicity on the RES system as well as possible immunogenicity have to be taken into account. In addition, the intracellular fate of the drug-carrier complex not only in normal but also in heterogenous pathological tissue should be clearly defined before rational claims of improved drug specificity can be made. 
SUMMARY
The anthraeycline antibiotics daunomycln and 14-hydroxydaunomyctn (adrlamycin, ADR) are very effective in the treatment of a number of malignancies. However, due to cardiotoxic side effects the cumulative dose may not exceed a certain value. We are developing ADR-polymer eonjugates (1,2) with the alm Of improving the therapeutic index by using the concept of the lysozomotroplc prodrug. A plasmastable polymer-bound drug is internalized by cells by pinocytosls and degraded In the lysozomal compartments by many digestive enzymes at an acidic pH (pH 4-5) releasing the free drug. We prepared a series of amlnorlbosyl-bound prodrugs of ADR using poly(a-L:glhtamle aeid), PGA as a carrier and different pepttdes as spacers (1,2). The eonjugates were studied for their capacity to inhibit the growth of mouse leukemia L1210 an T mouse melanoma B16 cells (1,2). The cytotoxlc actlvitylof the conjugates increases with increasing length of the spacer, but remains below (I-10%) that of free ADR. Our current studies include the plnocytosis of some of the ADR-polymer conjugates into cells using laser flow cytomerry and'laser microscopy as well as the release of ADH effected by papain as a representative enzyme for lysozomal enzymes. These studies may allow the optimization of the release of ADR from polymeric prodrugs. (2) Honoclonal antibody (IICA) against human milk Fat globule antigen ,was coupled to DTPA using the bieycli~ DTPA anhydride according to Layee et al (1982) and Hnato~ieh et al (1983) and ~as labelled ~ith Inlll using Iris acetate bufFered Inlll-exirlate aL pH7 or Ga67 as citrate pl17. Ihe Fresh labelled [lea sho,~ed no loss of biological uetlvity as measured iI~ an ELISA system. ]ndiual labelled FlEA was stored at 4U~ for seven days. l leA was dissolved either in phosphate buffered saline (PBS), 4.5% sucrose in PUS or in dextran solution, With respect to maintaining specific activity Inlll labelled MCA oas stable especially when sucrose 4.5% in PUS was used as solvent. Dextran solution was not the appropriate solvent mairltairling optimal stability of the labelled HCA, The [')CA maintained some sf its biological activity. A not labelled HCA preparation also stored 7 days at 40 s lost its biological activity to the same extend indicating that the 19ss was eat connected to the labelIing technique. A nude mouse ~ith an implanted human breast tumor intraperitoneally injected wlth [n111 labelled DTPA-FICA and uith eonspecifie Ga67 labelled DIPA-mouse IgG ~as imaged five days after injection. ]umor localization ~as improved after subtracting the Ga67 From the Inlll image. Albumin microspheres, containing magnetite, were prepared and their retention was studied in vitro and in vivo. In vitro a system was used in which a 70 cm straight tube (I.D. 1.5 mm) of silicone or tygon was conducted through a magnetic field. Saline or blood was pumped through the tube. At the beginning of the tubing technetium-labelled microspheres were introduced. Besides type of tubing and of fluids transported, also magnetic field strength, amount of magnetite in the spheres and fluid velocity were changed.
In the in vivo model the microspheres were introduced into the A. carotjs of a rat and retained in a silicone bypass of the aorta abdominalis or in the aorta abdominalis itself. The percentages of the microspheres retained in vivo were compared with the in vitro results. The two sorts of experiment showed a fair correlation. Microspheres have been proposed for the selective targeting crf cytotoxic drugs to tumors. Since organ distribution is dependent on the size and administration, it is reasonable to attempt targeting of mlcrospheres on this basis so that improved second and/or thzrd order targeting to tumors will be achieved. Biodegradable albumin microspheres with built-in cytostatic compounds are prepared using a water-in-oil technlque. The in vitro release of built-in drug shows a biphasic profile with a fast burst-effect followed by a slow first-order release. Due to the poor aqueous solubility, only small amounts of cytostatic drug can be incorporated into the spheres. Therefore, a microsuspension/emulsion procedure has been developed to associate maximum amounts of these drugs into a minimum amount of microspheres. This method increases the payload of,e.g, cisplatinum upto 65%. Microspheres have been labelled with 99m-Tc and 131-I. Ga,~a camera scintigraphy has been used to examine organ distribution and in rive pharmacokinetics of the labelled spheres. After intravenous administration, 15-35 micron microspheres are trapped in the lungs during 9 days. After intraarterial infusion via the hepatic artery these microspheres lodge completely in the liver. Intravenous delivery of I-5 micron microspheres labelled with 131-I results in uptake of the spheres in liver and spleen. After 18 hr no activity is observed in these organs anymore. Histological investigation has to be carried out to determlne the relationship between disappearance of the label and the microspheres. 
3.G. Fokkens
Since the seventies a number of research centra ~mainly universities) have concentrated their research on drug targetting. Although these research centra are very enthousiastic and optimistic, with as a consequence an exponentially increasing number of publications auout (the possibilities of) drug targeting, the pharmaceutical industries seem to hesitate to enter this research fielu.
From an industrial point of view there exist several reasons for this 'hesitating attitude'. The must important reasons are: I) unti~ now it has been proven incidentally and in very specific cases that the principle of drug targeting works in vivo; 2) pharmalogical properties of the drug might be altered drastically, which can result in toxieological problems; 3) drug carrier systems as well as 'modified drugs' can cause immunologic reactions; 4) only limited data on stability, sterility, pyrogenicity and production ~especially 'bulk' production) are available.
Neyertheless it can be expected that a number of targeted drugs will come on the market, since in the past few years several pharmaceutical companies started activities in this field. Lactosaminated human serum albumin (Ln-HSA) preparations with various amounts of galactosyl residues were prepared in order to study the pharmacokinetlc behavior of these potential drug carriers in isolated rat liver perfuslons. For this purpose lactose was coupled covalently to the e-NN 2 of lysine residues of HSA by reductive amination with cyanoborohydrlde. Labeling of two preparations, L 7-HSA and L23-NSA," was performed with the fluorochrome FITC. In order to follow the degradation products of the lactose-HSA compounds more quantitatively, a RP-HPLC gradient elution method was developed. The first order perfusate disappearance rates and the biliary appearance rates of the FITC-L -HSA were followed in isolated rat liver perfusions. No essential differences could be found in the rate of hepatic uptake of the two lactose-albumin fractions. On the other hand, a profound difference between the cellular routing as well as the biliary excretion rate of degradation products of the two derivatives was observed. It is concluded that in the case of the L7-conjugate but probably not in the case of the L23-derlvative the lysosomal degradation of the FITC-labeled protein represents the rate limiting step in the biliary excretion of fluorescent degra~tlon products. This study was conducted to elaborate a novel method for quantification of glycoprotein degradation in the intact liver. To this aim we coupled the well known fluorochrome FITC to asialo al-acid glycoprotein (ASOR). The covalent attachment (the molar F/P ratio averaged 1.0) of FITC to the glycoprotein did not significantly affect its perfusate disappearance (p<O.05). The first order disappearance rate was characterized by a t~=6.1+0.3 min (n=6), the clearance being II.2~0.6 ml.min-l(n=6).--The internalized FITC-laheled protein was degraded in the liver as demonstrated by an abundant excretion of free FITC-amino acid conjugates in the bile. The biliary appearance rate of these FITC containing degradation, nroducts after injection of FITC-labeled ASOR, was slow compared with experiments in which FITC itself or 5-aminofluorescein were injected. It was hypothetized therefore that lysosomal degradation of ASOR-FITC pro-" bably repgesents the rate limiting step in the excretion of FITC-mat6rial into bile. Treatment of an isolated perfused rat liver with varying doses (0.0]-5 mg) of the lysosomal protease inhibitor leupeptin did not influence clearance of ASOR-FITC from the perfusion medium being I0.8+2.0 ml/min (n=6). However in line with the above mentioned hypothesis leupeptin inhibited the production of cholephilic FITCmetabolites in a dose-dependent fashion, half maximal inhibition occurring at 2|0 nM (in the perfusion medium), corresponding with a dose of O.Oi mg leupeptin per I0 g liver. It is concluded that the rate of lysosomal degradation of the asialo glycoprotein in the intact liver can be determined by measuring the biliary excretion of fluorescent material originating from fluorescent probes covalently attached to it. This finding may greatly enhance the possibility of following the intracellular fate of endocytosed proteins and characterization of proteolytic function of hepatocytes in situ.
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